ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update

ObsEva (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today reported financial results for the fourth quarter and year ended December 31,2017, and provided a business update outlining recent corporate progress and upcoming milestones.

As quoted in the press release:

“2017 was a very important year for ObsEva as we became a public company, focused on designing, initiating, and enrolling clinical trials within our four ongoing development programs seeking to bring new treatment alternatives to women in need” said Ernest Loumaye, co-founder and Chief Executive Officer of ObsEva. “We look forward to delivering on our strategic, clinical and regulatory milestones for all three of our development compounds over the course of 2018”.  

Click here to read the full press release.